首页> 外文期刊>Cellular Physiology and Biochemistry >Huangqi Decoction Ameliorates Streptozotocin-Induced Rat Diabetic Nephropathy through Antioxidant and Regulation of the TGF-?2/MAPK/PPAR-?3 Signaling
【24h】

Huangqi Decoction Ameliorates Streptozotocin-Induced Rat Diabetic Nephropathy through Antioxidant and Regulation of the TGF-?2/MAPK/PPAR-?3 Signaling

机译:黄芪汤通过抗氧化和调节TGF-β2/ MAPK /PPAR-β3信号传导减轻链脲佐菌素诱导的大鼠糖尿病肾病

获取原文
           

摘要

>Background/Aims: Huangqi Decoction (HQD) has been traditionally used to treat diabetes mellitus in China. The present study was carried out to assess the protective effect of HQD on diabetic nephropathy (DN) using the streptozotocin-induced (STZ) diabetic rats. Methods: Diabetes was induced by a single intraperitoneal injection of STZ (60 mg/kg) in male Wistar rats. 40 diabetic rats were divided into 5 groups: vehicle-treated (DN group), 0.45, 0.15, 0.05 g/kg HQD-treated diabetic group (HQD group) and 1 mg/kg rosiglitazone-treated diabetic group (RGZ group). 16 normal rats were randomly divided into 2 groups: vehicle-treated normal control group (NC) and 0.45 g/kg HQD-treated normal control group (NC+0.45 g/kg HQD). At the end of 8-week experiment, we measured changes of renal pathological morphology, function, antioxidant enzyme levels and the activation of TGF-?2/PPAR-?3/MAPK signaling pathway. Results: After HQD treatment, renal function, including blood urea nitrogen (BUN), 24-h albuminuria and blood glucose level were improved significantly; meanwhile, impaired kidney redox balance was diminished in diabetic rats. The activation of TGF-?2, phospho-JNK, phospho-p44/42, p47 and p42 phox was blocked and the decrease in PPAR-?3 in diabetic rats was attenuated by treatment with HQD in a dose-dependent manner. Conclusion: These results suggest that HQD shows therapeutic efficacy in DN characterized by renal dysfunction and pathological changes through hypoglycemic and antioxidant effects.
机译:> 背景/目的: 黄芪汤(HQD)在中国传统上用于治疗糖尿病。本研究旨在评估链脲佐菌素诱导的(STZ)糖尿病大鼠对HQD对糖尿病肾病(DN)的保护作用。 方法: 雄性Wistar大鼠腹膜内一次注射STZ(60 mg / kg)可诱发糖尿病。 40只糖尿病大鼠分为5组:媒介物治疗组(DN组),0.45、0.15、0.05 g / kg HQD治疗组糖尿病组(HQD组)和1 mg / kg罗格列酮治疗糖尿病组(RGZ组)。将16只正常大鼠随机分为2组:媒介物处理的正常对照组(NC)和0.45 g / kg HQD处理的正常对照组(NC + 0.45 g / kg HQD)。在8周的实验结束时,我们测量了肾脏病理形态,功能,抗氧化酶水平以及TGF-β2/PPAR-β3/ MAPK信号通路的激活情况。 结果: HQD治疗后,包括血尿素氮(BUN),24小时白蛋白尿和血糖水平在内的肾功能得到了明显改善;同时,糖尿病大鼠肾脏氧化还原平衡受损。通过以剂量依赖的方式用HQD治疗,阻断了糖尿病大鼠中TGF-β2,磷酸化JNK,磷酸化-p44 / 42,p47和p42-phox的活化,并减轻了PPAR-β3的降低。 结论: 这些结果表明,HQD对DN具有治疗作用,其特点是肾功能不全,并通过降血糖和抗氧化作用改变病理状态。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号